Navigation Links
Trubion Announces Initiation of Phase 1 Study of SBI-087 for the Treatment of Rheumatoid Arthritis
Date:4/21/2008

SMIP(TM) technology to create a portfolio of product candidates with customized mechanisms of action in an effort to optimize patient safety, efficacy and convenience.

"Initiation of the SBI-087 Phase 1 clinical trial marks an important milestone in advancing our pipeline through our collaboration with Wyeth," said Peter Thompson, M.D., FACP, president, CEO and chairman of Trubion. "We believe SBI-087 and TRU-015 together will play an important role in improving patient care and helping us establish category leadership in autoimmune and inflammatory disease markets."

About Trubion

Trubion is a biopharmaceutical company that is creating a pipeline of novel protein therapeutic product candidates to treat autoimmune and inflammatory diseases and cancer. The company's mission is to develop a variety of first-in-class and best-in-class product candidates, customized for optimal safety, efficacy, and convenience that it believes may offer improved patient experiences. Trubion's current product candidates are novel single- chain protein, or SMIP(TM), therapeutics, and are designed using its custom drug assembly technology. Trubion's product pipeline includes CD20-directed candidates such as TRU-015 and SBI-087 for autoimmune and inflammatory diseases, developed under the company's Wyeth collaboration. Trubion's proprietary product candidate, TRU-016, is a novel CD37-targeted therapy for the treatment of B-cell malignancies currently in Phase 1/2 clinical evaluation. In addition to Trubion's current product candidates, the company is also developing additional alliance and proprietary product candidates that build on its product development experience. More information is available in the investors section of Trubion's website: http://investors.trubion.com.

Forward-Looking Statements

Certain statements in this release may constitute "forward-looking statements" within the meaning of
'/>"/>

SOURCE Trubion Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Trubion Announces Preliminary Analysis of Phase IIb Results With TRU-015 in Rheumatoid Arthritis
2. Trubion Pharmaceuticals Announces Presentation of Positive Data From Phase IIb and Re-treatment Studies With TRU-015 in Patients With Rheumatoid Arthritis
3. Trubion Announces Initiation of Phase I/II Clinical Trial of TRU-015 for the Treatment of B-Cell Non-Hodgkins Lymphoma
4. Trubion Initiates Phase 1/2 Study of TRU-016 in CLL, Announces Next-Generation Product Candidate for RA and Provides Product Pipeline Update
5. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
6. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
7. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
8. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
9. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
10. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
11. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... , July 30, 2014 Stryker brand ambassadors ... week at the 3M Championship Champions Tour event near ... in Blaine . Stryker is the official joint ... Starting Friday, August 1 st through Sunday, August ... Mobility Zone; an on-site joint health destination located in the Pioneer ...
(Date:7/30/2014)... , July 30, 2014 Silicon Valley Bank, ... a study today that examines the merger, acquisition ... device companies.  According to the annual report based on ... potential returns since SVB started tracking the data in ... IPO.  Built on solid healthcare M&A activity over the ...
(Date:7/30/2014)... YORK , July 30, 2014 ACCESS ... for oncology supportive care, announced that its novel product ... in an article on OncLive.com titled, "Study Finds Mouth ... Cancers."  Dr. Steve Sonis , a leading expert ... seen in the oncology community for evidence-based strategies for ...
Breaking Medicine Technology:Stryker Brand Ambassadors Fred Funk And Hal Sutton Set To Play At 3M Championship 2Stryker Brand Ambassadors Fred Funk And Hal Sutton Set To Play At 3M Championship 3Stryker Brand Ambassadors Fred Funk And Hal Sutton Set To Play At 3M Championship 4Stryker Brand Ambassadors Fred Funk And Hal Sutton Set To Play At 3M Championship 5Report: Biopharma and Medical Device Companies Beat Historic Investment Returns 2Report: Biopharma and Medical Device Companies Beat Historic Investment Returns 3Access Pharmaceuticals Featured On OncLive.com 2Access Pharmaceuticals Featured On OncLive.com 3
... the global leader in technology support and BPO services ... today the opening of its new Global Operations Center ... city of Dalian, will specialize in providing services in ... sponsors and clinical research organizations. With dramatic ...
... ARBOR, Mich., April 7, 2011 Adeona Pharmaceuticals, Inc. (AMEX: ... serious central nervous system diseases, announced today that it has ... its common stock at approximately $2.0725 per share to a ... million in gross proceeds. The investor will also receive warrants ...
Cached Medicine Technology:C3i Opens Asia Language Center in Dalian, China 2Adeona to Raise $3.5 Million in Registered Direct Offering 2Adeona to Raise $3.5 Million in Registered Direct Offering 3
(Date:7/30/2014)... The Europe commercial aviation actuation system market ... is expected to reach $1,686.72 million by 2019 at ... an exclusive range of opportunities and challenges which will ... has seen slumps in the past, yet the sector ... to its long-term growth rate of approximately 5 % ...
(Date:7/30/2014)... (PRWEB) July 30, 2014 Foot ... Seminar schedule, a series highlighted by eight speakers, 29 ... from seven chiropractic colleges. The seminars cover a range ... from low back stabilization to imaging. The Foot ... professionals by providing informative, entertaining courses that also offer ...
(Date:7/30/2014)... N.J. The household income of its residents is ... or low rates of avoidable hospital visits conditions that ... health care settings if treated at an early stage, according ... State Health Policy (CSHP). , An analysis of hospital ... low-income communities in New Jersey found that as an area,s ...
(Date:7/30/2014)... It is said that necessity is the ... true as a product sponsor for Lash Wars 2014 ... past June. , Lash Affair believes in the ... the eyelash industry through collaboration so Jenelle Paris, Founder and ... NEESA ’s event. Lash Affair’s mission dovetails nicely with ...
(Date:7/30/2014)... one in every twenty elderly American adults is being ... This burgeoning public health crisis especially affects poor and ... makers, researchers, and any citizen who cares about the ... Peterson of Weill Cornell Medical College in the US. ... on elder abuse, the findings of which appear in ...
Breaking Medicine News(10 mins):Health News:Europe Aviation Actuation System Market is Expected to Reach $1,686.72 Million in 2019 - New Report by MicroMarket Monitor 2Health News:Europe Aviation Actuation System Market is Expected to Reach $1,686.72 Million in 2019 - New Report by MicroMarket Monitor 3Health News:Europe Aviation Actuation System Market is Expected to Reach $1,686.72 Million in 2019 - New Report by MicroMarket Monitor 4Health News:Foot Levelers Announces 2014 Fall Seminars Series Schedule 2Health News:Income is a major driver of avoidable hospitalizations across New Jersey 2Health News:Income is a major driver of avoidable hospitalizations across New Jersey 3Health News:Lash Affair Launches a New Product as Sponsor of the First U.S. Lash Extension Competition 2Health News:Older adults are at risk of financial abuse 2
... International SOS Assistance, Inc. today was awarded the ... Department of Defense TRICARE Overseas Program. Since 1998, International SOS ... and their families receive the highest quality care, no matter ... States and Puerto Rico. , Under this new ...
... given early in pregnancy might save infants most at ... -- U.S. researchers are testing a new approach in ... while they,re still in the womb. , The new ... cells that have been treated to speed and improve ...
... 16 The National Trauma Institute, a national non-profit ... States, announced its first Request for Proposals (RFP) for ... practice and save lives. , The organization will award ... take place in 2010. "Historically, trauma research has been ...
... THOUSAND OAKS, Calif. and COLLEGEVILLE, Pa., Oct. 16 ... PFE ), today announced new scientific data about ENBREL ... (ACR) Scientific Meeting in Philadelphia, Pa., from Oct. 17-21, ... years of collective clinical experience. , "The ...
... public forum for discussing the latest updates, information on H1N1/Swine flu ... public are invited to submit questions for inclusion in a two-part ... 22, from 10 a.m. - noon on Twitter. , Sandro ... Health System and VA Ann Arbor Healthcare System, will answer questions ...
... comment on media reports this week that France is ... internet, to conform to European rights. Although Budget Minister ... news is disappointing given the drop in heart attack ... Professeur Ph.Gabriel STEG (Universit Paris VII, Centre Hospitalier Bichat-Claude ...
Cached Medicine News:Health News:International SOS Awarded TRICARE Overseas Program Contract 2Health News:Transplant May Treat Metabolic Disorders in Womb 2Health News:National Trauma Institute Announces $600,000 in Funding for Trauma Research 2Health News:Enbrel(R) (etanercept) Data to be Presented at the 2009 American College of Rheumatology Scientific Meeting 2Health News:Enbrel(R) (etanercept) Data to be Presented at the 2009 American College of Rheumatology Scientific Meeting 3Health News:Enbrel(R) (etanercept) Data to be Presented at the 2009 American College of Rheumatology Scientific Meeting 4Health News:Enbrel(R) (etanercept) Data to be Presented at the 2009 American College of Rheumatology Scientific Meeting 5Health News:Enbrel(R) (etanercept) Data to be Presented at the 2009 American College of Rheumatology Scientific Meeting 6Health News:Enbrel(R) (etanercept) Data to be Presented at the 2009 American College of Rheumatology Scientific Meeting 7Health News:Enbrel(R) (etanercept) Data to be Presented at the 2009 American College of Rheumatology Scientific Meeting 8Health News:Enbrel(R) (etanercept) Data to be Presented at the 2009 American College of Rheumatology Scientific Meeting 9Health News:ESC press statement : Cigarettes on sale on the internet 2Health News:ESC press statement : Cigarettes on sale on the internet 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: